GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pegaptanib   Click here for help

GtoPdb Ligand ID: 6836

Synonyms: EYEOO1 | Macugen® | NX183 | pegaptanib sodium
Approved drug
pegaptanib is an approved drug (FDA (2004), EMA (2006))
Compound class: Nucleic acid
Comment: Pegaptanib is a RNA oligonucleotide aptamer that acts as a vascular endothelial growth factor A antagonist, anti-angiogenic agent.
It is a 28-mer RNA oligonucleotide that is covalently linked to two branched 20-kD polyethylene glycol (PEG) chains. Pegaptanib binds to the 165 isoform of VEGFA. It is formulated as a sodium adduct.
The basic nucleotide sequence has modified nucleotides and a 5' pentylamino linker that acts as the PEG anchor.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. (2004)
Pegaptanib for neovascular age-related macular degeneration.
N Engl J Med, 351 (27): 2805-16. [PMID:15625332]
2. Nimjee SM, Rusconi CP, Sullenger BA. (2005)
Aptamers: an emerging class of therapeutics.
Annu Rev Med, 56: 555-83. [PMID:15660527]